<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000739953"><TermName>bosutinib</TermName><TermPronunciation>(bah-SOO-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat chronic  myelogenous leukemia (CML). It is used in patients who cannot be treated with or have not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Bosutinib blocks the action of BCR-ABL and other proteins, which may help keep cancer cells from growing and may kill cancer cells. It is a type of tyrosine kinase inhibitor. Also called Bosulif.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000742086" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bosutinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000742085" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bosutinib&quot;" language="es" id="_4"/><SpanishTermName>bosutinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar la leucemia mielógena crónica (LMC).   Se usa para pacientes que no se pueden tratar con otro tratamiento o que no mejoraron con otra terapia. También está en estudio para tratar otros tipos de cáncer.   impide la acción de BCR-ABL y otras proteínas; esto puede lograr que se formen o eliminar las células cancerosas. Es un tipo de inhibidor de la tirosina cinasa. También se llama Bosulif.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2012-09-13</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000739892">Bosutinib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
